Incidence and associated risk factors of antituberculosis drug-induced hepatotoxicity among hospitalised patients in Wuhan, China

2020 ◽  
pp. ejhpharm-2020-002433
Author(s):  
Na Xu ◽  
Jing Xiang Yang ◽  
Jian Yang
Keyword(s):  
Risk Factors ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Hospitalised Patients ◽  
Associated Risk Factors

Pressure ulcer incidence in acute care settings: a multicentre prospective study

2021 ◽  
Vol 30 (11) ◽  
pp. 930-938
Author(s):  
Ma'en Aljezawi
Keyword(s):  
Risk Factors ◽  
Acute Care ◽  
Pressure Ulcer ◽  
Conflicts Of Interest ◽  
White Blood Cells ◽  
Albumin Level ◽  
Advisory Panel ◽  
Hospitalised Patients ◽  
Acute Care Settings ◽  
Associated Risk Factors

Objective: Pressure ulcers (PUs) are one of the most commonly occurring complications in hospitalised patients. Knowing the size of the problem and its risk factors will help in preventing it. The aim of this study is to measure the incidence of PUs in acute care settings in Jordan and to explore associated risk factors. Method: A prospective incidence study for hospitalised patients in Jordan according to the European Pressure Ulcer Advisory Panel methodology. All patients admitted into four Jordanian hospitals over a period of six months were included. Results: The cumulative incidence rate was 0.48%. Using multivariate analysis, a low albumin level, elevated white blood cells, incontinence and having more chronic illnesses were significantly associated with acquiring PUs. Conclusion: Incidence of PUs in Jordan is lower when compared with other parts of the world; this could be related to the relatively younger Jordanian population compared with other populations. Declaration of interest: The author has no conflicts of interest to declare.

scholarly journals ANTI-TUBERCULAR DRUG INDUCED HEPATOTOXICITY: ASSOCIATED RISK FACTORS UNDER RNTCP-DOTS PULMONARY TUBERCULOSIS PATIENTS.

2016 ◽  
Vol 4 (8) ◽  
pp. 1372-1376
Author(s):  
Ishan Parasher ◽  
◽  
Suryakant Nagtilak ◽  
Amit Jha ◽  
Naresh kumar ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pulmonary Tuberculosis ◽  
Drug Induced ◽  
Tuberculosis Patients ◽  
Associated Risk Factors

scholarly journals Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens

2020 ◽  
Author(s):  
Paola Nicoletti ◽  
Harshad Devarbhavi ◽  
Ashish Goel ◽  
Radha Venkatesan ◽  
Chundamannil E. Eapen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Injury ◽  
Genetic Risk ◽  
Genetic Risk Factors ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Drug Regimens

scholarly journals Prevalence of difficult venous access and associated risk factors in highly complex hospitalised patients

2017 ◽  
Vol 26 (23-24) ◽  
pp. 4267-4275 ◽  
Author(s):  
Victoria Armenteros-Yeguas ◽  
Lucía Gárate-Echenique ◽  
Maria Aranzazu Tomás-López ◽  
Estíbaliz Cristóbal-Domínguez ◽  
Breno Moreno-de Gusmão ◽  
...  
Keyword(s):  
Risk Factors ◽  
Venous Access ◽  
Hospitalised Patients ◽  
Associated Risk Factors ◽  
Difficult Venous Access

scholarly journals Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors

2021 ◽  
Vol 17 (1) ◽  
pp. 1-7
Author(s):  
Dania Abu-Naser ◽  
Sara Gharaibeh ◽  
Ahmad Z. Al Meslamani ◽  
Qais Alefan ◽  
Renad Abunaser
Keyword(s):  
Risk Factors ◽  
Extrapyramidal Symptoms ◽  
Drug Induced ◽  
Gender And Age ◽  
High Incidence ◽  
History Of ◽  
Baseline Factors ◽  
The Difference ◽  
Health Database ◽  
Associated Risk Factors

Background: Extrapyramidal Symptoms (EPS) are unwanted symptoms commonly originating from the use of certain medications. The symptoms can range from minimal discomfort to permanent involuntary muscular movements. The aims of the study were to examine the incidence of drug-induced extrapyramidal symptoms (di-EPS), associated risk factors, and clinical characteristics. Methods: This is a retrospective, observational study of di-EPS conducted in outpatient clinics of Jordan using the longitudinal health database (Hakeem®) for data collection. Patients who received drugs with the risk of EPS during the period 2010-2020 were included and followed. Patients with any of the known underlying conditions that may cause EPS or were currently taking drugs that may mask the symptoms were excluded. Gender and age-matched control subjects were included in the study. The Statistical Package for Social Science (SPSS®) version 26 was used for data analysis. Results: The final dataset included 34898 exposed patients and 69796 matched controls. The incidence of di-EPS ranged from 9.8% [Amitriptyline 25mg] to 28.9% (Imipramine 25mg). Baseline factors associated with a significantly higher risk of developing di-EPS were age {HR: 1.1 [95%CI: 0.8-1.2, p=0.003], smoking {HR: 1.7 (95%CI: 1.3-2.2), p=0.02}, tremor history {HR: 7.4 (95%CI: 5.9-8.3), p=.002} and history of taking antipsychotics {HR: 3.9, (95% CI: 2.5-4.6), p=0.001}. Patients taking paroxetine {HR: 8.6 [95%CI: 7.4-9.8], p=.0002},imipramine {HR: 8.3, [7.1-10.5], p=0.01}, or fluoxetine {HR: 8.2 (95%CI: 6.8-9.3), p=.006} had a significantly higher risk of developing di-EPS compared to patients taking citalopram. Myoclonus, blepharospasm, symptoms of the basal ganglia dysfunction, and organic writers' cramp were reported among participants. Conclusion: Patients treated with paroxetine, imipramine, fluoxetine, or clomipramine had a higher risk of developing di-EPS than patients treated with citalopram. The difference in gender was not significantly related to di-EPS development. Whereas age, smoking, and history of taking antipsychotics were significantly associated with di-EPS development. Key findings: • High incidence of drug-induced extrapyramidal symptoms (di-EPS) was reported • Age, smoking, tremor history, and history of taking antipsychotics were risk factors of drug-induced extrapyramidal symptoms. • Patients taking paroxetine, imipramine or fluoxetine had a significantly higher risk of developing di-EPS compared to patients taking citalopram

scholarly journals Faktor Risiko Terjadinya Hepatotoksisitas Imbas Obat Antituberkulosis pada Pasien HIV/AIDS

2017 ◽  
Vol 4 (1) ◽  
pp. 23
Author(s):  
Lies Luthariana ◽  
Teguh H. Karjadi ◽  
Irsan Hasan ◽  
C. Martin Rumende
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Control Group ◽  
Case Group ◽  
Antituberculosis Drug ◽  
Aids Patients ◽  
Drug Induced ◽  
Hiv Aids

Pendahuluan. Hepatotoksisitas imbas antituberkulosis (OAT) banyak didapatkan pada pasien HIV/AIDS. Beberapa faktor risiko terjadinya hepatotoksisitas imbas obat seperti alkoholisme, infeksi hepatitis B maupun C, abnormalitas transaminase, status gizi kurang, penggunaan beberapa obat hepatotoksik secara bersamaan, banyak didapatkan pada pasien-pasien tersebut. Dengan karakteristik pasien HIV/AIDS yang berbeda dengan di negara lain maka diperlukan penelitian tersendiri tentang risiko terjadinya hepatotoksisitas imbas OAT pada pasien tersebut di Indonesia. Penelitian ini dilakukan untuk mengetahui faktor risiko terjadinya hepatotoksisitas imbas OAT pada pasien HIV.Metode. Desain penelitian ini adalah studi retrospektif kasus-kontrol dengan matching usia, jenis kelamin, regimen OAT dan konsumsi alkohol. Faktor risiko yang diteliti adalah koinfeksi hepatitis C, hepatitis B, konsumsi obat hepatotoksik lainnya, dan abnormalitas nilai awal SGPT dan atau billirubin total.Hasil. Pada penelitian ini diperoleh 33 kasus dan 33 kontrol. Proporsi subjek dengan koinfeksi hepatitis C sebesar 82% pada kasus dan 76% pada kontrol, sedangkan proporsi subjek dengan koinfeksi hepatitis B sebesar 18% pada kasus dan 6% pada kontrol. Subjek dengan nilai SGPT awal meningkat didapatkan pada kelompok kasus sebesar 51,5% dan pada kontrol sebesar 12%. Sementara itu, proporsi subjek yang menggunakan obat hepatotoksik lainnya sebesar 54,5% pada kasus dan 42,4% pada kontrol. Pada analisis bivariat, hanya nilai SGPT awal yang meningkat yang berhubungan dengan kejadian hepatotoksisitas imbas OAT (OR=7,5; IK95% 1,72-32,80; p < 0,05).Simpulan. Nilai SGPT awal yang meningkat dapat meningkatkan risiko terjadinya hepatotoksisitas imbas OAT pada pasien HIV/AIDS sebesar 7,5 kali. Tidak didapatkan hubungan koinfeksi hepatitis C, hepatitis B dan penggunaan obat hepatotoksik lainnya dengan kejadian hepatotoksisitas imbas OAT pada pasien HIV/AIDS.Kata Kunci: hepatotoksisitas imbas OAT, HIV/AIDS, tuberkulosis Risk Factors of Antituberculosis Induced-Hepatotoxicity among HIV/AIDS PatientsIntroduction. Antituberculosis (ATT) induced hepatotoxicity is commonly found among HIV/AIDS patients. Several risk factor related to drug-induced hepatotoxicity such as alcoholism, hepatitis B or hepatitis C infection, abnormal baseline aminotransferase/bilirubin, poor nutritional status and concomitant hepatotoxic drugs consumption, are usually found in these patients. This study was conducted to evaluate risk factor of ATT-induced hepatotoxicity in HIV/AIDS patients. Methods. This is a case control retrospective study with matching of age, sex, antituberculosis regimen, and alcohol consumption. Risk factors evaluated are hepatitis C and hepatitis B coinfection, concomitant hepatotoxic drugs consumption, abnormal baseline aminotransferase and or bilirubin.Results. We collected data of 33 cases and 33 controls We found 82% subjects in case group and 76% subjects in control group have hepatitis C coinfection; 18% subjects in case group and 6% subjects in control group have hepatitis B coinfection. Fifty four point five percent (54.5%) subjects in case group and 42.4% subjects in control group consume other hepatotoxic drugs. Elevated baseline ALT level was found in 51.5% subjects in case group and 12% subject in control group. Bivariate analysis showed that the risk of hepatotoxicity was higher in patients with elevated baseline ALT level (OR=7.5; 95% CI 1,7232,80; p < 0,05).Conclusions. Elevated baseline ALT level will increase antituberculosis drug induce hepatotoxicity risk up to 7.5 times. There were no association between hepatitis C, hepatitis B, concomitant hepatotoxic drugs consumption and antituberculosis drug-induced hepatotoxicity in HIV/AIDS patients.

scholarly journals TL 18094 - Fluorquinolones and the risk of Achilles tendon disorders

2019 ◽  
Vol 13 (Supl 1) ◽  
pp. 77S
Author(s):  
Alexandre Leme Godoy-Santos ◽  
Miguel Srougi ◽  
Homero Bruschini ◽  
Cesar de Cesar Netto ◽  
Lucas Furtado ◽  
...  
Keyword(s):  
Risk Factors ◽  
Achilles Tendon ◽  
Case Reports ◽  
Tendon Injury ◽  
Achilles Tendinopathy ◽  
The Body ◽  
Current Evidence ◽  
Drug Induced ◽  
Concurrent Use ◽  
Associated Risk Factors

Introduction: Achilles FQ-associated tendinopathy was first reported by Bailey et al. in 1983. Since then, nearly 200 case reports related to FQ-associated tendon injury have been published, as well as some case control and cohort studies. Today, drug-induced tendinopathy is accepted as a class effect of FQ. The Achilles tendon is affected in 90% of cases of FQ-related tendinopathy and rupture. Objective: To evaluate current evidence for the association between fluoroquinolones and Achilles tendinopathy and to identify associated risk factors that increase the incidence of this complication. Methods: We conducted a computerized search of the relevant scientific literature from 1988 to 2018 using electronic databases, including PubMed, Medline and Scopus. The search terms were fluoroquinolone-related tendinopathy. Eligible studies were any available reports of fluoroquinolone-related tendinopathy (tendinitis, tendon pain, or rupture); animal and human histologic studies were included. Data collected included any cases of fluoroquinolone-related tendinopathy, the particular tendon affected, type of FQ, dosage, and concomitant risk factors. Results: The references selected were reviewed by all authors and judged based on their contribution to the body of knowledge on this topic. The conduct and validity of any clinical studies were carefully considered, and the outcomes of management protocols were carefully scrutinized. Case reports mentioning a specific association with the condition that were thought to be relevant to the discussion were included. Only papers that made a significant contribution to understanding of this condition were included in the review. Thus, a total of 560 abstracts were screened, 79 of which were directly related to FQ-associated Achilles tendinopathy or tendon rupture. Conclusion: The association between the use of fluoroquinolone antibiotics and Achilles tendon disorders is well-established in the medical literature. We found that male gender, advanced age, normal BMI, chronic renal failure and concurrent use of corticosteroids increases the risk of Achilles tendon pathology. Caution should be exercised during the utilization of this antibiotic class in patients with these characteristics

Sign in / Sign up

Export Citation Format

Share Document